Novavax Initiates P-II Trial of COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
- The company initiates the P-II trial, conducted in 2 parts evaluating the combination of Novavax's COVID-19 vaccine NVX-CoV2373, quadrivalent influenza vaccine candidate & patented saponin-based Matrix-M adjuvant in adults aged 50-80yrs. Study plans to initiate enrolment of ~2300 patients across multiple sites in Australia & New Zealand
- The primary & secondary objectives are to evaluate the safety, tolerability & immune responses to multiple formulations of CIC & influenza vaccine candidates
- Initial findings are expected in mid-year 2023 & these data will support the P-III trials for combination candidates. Multiple regulatory bodies incl. the US FDA, EC & WHO have approved the COVID-19 vaccine, which is under review for additional indications & populations
Ref: PR Newswire | Image: Novavax
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.